Mereo Total Assets from 2010 to 2024
| MREO Stock | USD 3.68 0.10 2.79% |
Total Assets | First Reported 2015-12-31 | Previous Quarter 96.1 M | Current Value 88.7 M | Quarterly Volatility 126.1 M |
Check Mereo BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mereo BioPharma's main balance sheet or income statement drivers, such as Interest Income of 2.2 M, Discontinued Operations of 0.0 or Interest Expense of 2.9 M, as well as many indicators such as Price To Sales Ratio of 101, Dividend Yield of 0.0 or PTB Ratio of 31.65. Mereo financial statements analysis is a perfect complement when working with Mereo BioPharma Valuation or Volatility modules.
Mereo | Total Assets |
Latest Mereo BioPharma's Total Assets Growth Pattern
Below is the plot of the Total Assets of Mereo BioPharma Group over the last few years. Total assets refers to the total amount of Mereo BioPharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Mereo BioPharma Group books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Mereo BioPharma's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mereo BioPharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 66.5 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Mereo Total Assets Regression Statistics
| Arithmetic Mean | 92,972,847 | |
| Geometric Mean | 90,979,105 | |
| Coefficient Of Variation | 20.84 | |
| Mean Deviation | 16,366,107 | |
| Median | 96,335,477 | |
| Standard Deviation | 19,372,259 | |
| Sample Variance | 375.3T | |
| Range | 63.5M | |
| R-Value | (0.59) | |
| Mean Square Error | 262T | |
| R-Squared | 0.35 | |
| Significance | 0.02 | |
| Slope | (2,569,071) | |
| Total Sum of Squares | 5254T |
Mereo Total Assets History
Other Fundumenentals of Mereo BioPharma Group
Mereo BioPharma Total Assets component correlations
Click cells to compare fundamentals
About Mereo BioPharma Financial Statements
Mereo BioPharma investors utilize fundamental indicators, such as Total Assets, to predict how Mereo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 66.5 M | 70.1 M | |
| Intangibles To Total Assets | 0.02 | 0.02 |
Pair Trading with Mereo BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Mereo Stock
| 0.76 | VALN | Valneva SE ADR Downward Rally | PairCorr |
| 0.67 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Mereo Stock
| 0.44 | RNXT | RenovoRx | PairCorr |
| 0.41 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.33 | NXGLW | NexGel Warrant | PairCorr |
The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.
The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Mereo BioPharma Correlation against competitors. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 0.007 | Return On Assets (0.24) | Return On Equity (0.48) |
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.